UroGen Pharma Ltd
URGN
40.70
-0.73
-1.76%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
40.70
-0.73
-1.76%
Live - 5344 symbols - heartbeat 105s ago
· 2026-10-08 08:07
Pre-market
40.41
-0.71%
After-hours
40.50
-0.49%
- Market cap
- 1.99B
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on URGN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 5 analysts
Buy
Avg price target
60.20 +47.9%
Price target rangecurrent 40.70
Low48.00
Avg60.20
High75.00
Buy 80%
Hold 20%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-21 | H.C. Wainwright | -- | BUY | 75.00 |
| 2026-08-20 | H.C. Wainwright | -- | BUY | 75.00 |
| 2026-08-11 | H.C. Wainwright | -- | BUY | 75.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 75.00 |
| 2026-08-06 | Oppenheimer | -- | BUY | 60.00 |
| 2026-08-05 | TD Cowen | -- | BUY | 60.00 |
| 2026-08-05 | Goldman Sachs | -- | HOLD | 48.00 |
| 2026-08-05 | Guggenheim | -- | BUY | 58.00 |
| 2026-07-21 | Guggenheim | -- | BUY | 42.00 |
| 2026-07-20 | TD Cowen | -- | BUY | 50.00 |
| 2026-07-16 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-07-16 | Oppenheimer | -- | BUY | 50.00 |
| 2026-07-15 | Goldman Sachs | -- | HOLD | 44.00 |
| 2026-07-09 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-06-16 | TD Cowen | -- | BUY | 35.00 |
| 2026-06-03 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-05-26 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-05-19 | Oppenheimer | -- | BUY | 40.00 |
| 2026-05-18 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-05-15 | TD Cowen | -- | BUY | 35.00 |
| 2026-05-11 | Ladenburg Thalmann | -- | BUY | 43.00 |
| 2026-05-11 | H.C. Wainwright | -- | BUY | 45.00 |
| 2026-05-07 | Oppenheimer | -- | BUY | 40.00 |
| 2026-05-06 | TD Cowen | -- | BUY | 35.00 |
| 2026-04-22 | H.C. Wainwright | -- | BUY | 40.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | -- | ±16.78% | +16.31% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±16.51% | +10.16% (in line) |
| 2025/Q4 | 2026-03-02 | -- | ±19.22% | -12.35% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±29.01% | +21.91% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±13.32% | -7.10% (in line) |
| 2025/Q1 | 2025-05-12 | -- | ±25.06% | +7.32% (in line) |
| 2024/Q4 | 2025-03-10 | -- | ±18.71% | +1.02% (in line) |
| 2024/Q3 | 2024-11-06 | -- | ±14.91% | +0.25% (in line) |
| 2024/Q2 | 2024-08-13 | -- | ±19.85% | +3.10% (in line) |
| 2024/Q1 | 2024-05-13 | -- | ±17.20% | +2.59% (in line) |
| 2023/Q4 | 2024-03-14 | -- | ±12.82% | -17.97% (beat) |
| 2023/Q3 | 2023-11-14 | -- | ±44.46% | -0.68% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:07:16 · For reference only, not investment advice and not tailored to your situation.